Podcasts about GSK

Play Episode Listen Later Jun 19, 2026 4:51

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The industry continues to evolve, with significant scientific advancements, regulatory updates, and strategic business moves shaping the landscape. Let's delve into these developments, starting with some key insights from oncology. In the realm of oncology, minimal residual disease (MRD) is becoming increasingly pivotal. Tumor-informed MRD is being leveraged to design more intelligent trials and interpret early responses, aiding in navigating developmental risks more effectively. This approach was a focal point of discussions at the American Society of Clinical Oncology's annual meeting, where experts emphasized the need to translate precision oncology discoveries into patient care, aiming to surmount existing challenges. The focus on MRD in oncology could lead to earlier detection of treatment responses and personalized therapeutic approaches. Verastem Oncology recently revisited its strategy concerning its combination treatment of avutometinib plus defactinib for metastatic pancreatic cancer. While clinical trials produced moderate results, the company is now redirecting focus toward other promising candidates in its pipeline. Similarly, Novocure faced setbacks as its tumor-treating electric fields device did not achieve its primary endpoint in a Phase 3 glioblastoma trial. These outcomes highlight the persistent challenges in tackling aggressive brain cancers. On the regulatory front, Spero Therapeutics achieved a significant milestone with FDA approval for Utebzi to treat complicated urinary tract infections. This approval marks a turnaround from a previous rejection four years ago, facilitated through a partnership with GSK. Meanwhile, in Europe, Cinnagen secured approval for Zandoriah, a biosimilar of teriparatide, to treat osteoporosis in adults—a testament to their investment in infrastructure and manufacturing capabilities. The industry also sees growing interest in cell therapy automation, with companies like Cellares and Ori Biotech leading the charge. These advancements reflect an industry-wide push towards more efficient manufacturing processes for cell therapies. In metabolic health, Novo Nordisk's oral GLP-1 drug Wegovy has gained significant traction due to its brand familiarity among healthcare providers, crucial in its competition with Eli Lilly's Foundayo. Market trends reveal competitive dynamics within obesity treatments as Novo Nordisk's oral Wegovy outpaces Eli Lilly's offerings due to strong brand recognition. Biogen's acquisition of Raythera for $1 billion underscores its strategic intent to enhance its portfolio with promising preclinical immunology assets. Such acquisitions highlight broader industry strategies focusing on expanding pipelines through targeted investments. This move aligns with Biogen's focus on autoimmune diseases and enhances its preclinical portfolio. In business development news, LabGenius Therapeutics partnered with LG Chem to utilize AI and machine learning for designing multispecific antibodies targeting tumors. This collaboration highlights the growing importance of artificial intelligence in accelerating drug discovery processes within oncology. Clinical trials continue to yield promising results. F2G and Shionogi's antifungal small molecule olorofim demonstrated efficacy comparable to Ambisome in treating invasive aspergillosis—an advancement crucial for infectious diseases with limited treatment options. D&D Pharmatech's Zabopegdutide showed an impressive improvement rate in fibrosis during Phase 2 trials for metabolic dysfunction-associated steatohepatitis, emphasizing the potential of protein-based therapies in treating metabolic liver disorders. Corporate launches reflect strategic maneuvers aimed at advancing therapeutic developments. Innoviva introduced Nortiva Bio to focus on long-acting oral medicines using acquired platform technology from Lyndra Therapeutics—aiming to revolutionize women's health through sustained-release formulations. The financial landscape also shows active movement, exemplified by Kardigan's $400 million IPO aimed at progressing cardiovascular drugs into advanced trials. Alvotech's public offering signals a commitment to biosimilar medicines—a sector poised for growth due to rising demand for cost-effective biologic therapies. Overall, these developments reflect a robust innovation pipeline within the pharmaceutical and biotech industries as they strategically address complex diseases through novel therapies and technologies. As scientific progress accelerates alongside strategic corporate actions, these changes promise enhanced patient care outcomes through groundbreaking treatments that cater to unmet medical needs worldwide.Support the show

ai europe market corporate phase fda ipo clinical american society glp pharma biotech tumors approves wegovy eli lilly acquires novo nordisk gsk mrd biogen fda approval glioblastoma clinical oncology biosimilar lg chem biote shionogi alvotech innoviva

Synthesizable by Design: Rethinking AI's Role in Small Molecule Drug Discovery

Data in Biotech

Play Episode Listen Later Jun 17, 2026 59:29

In this episode of Data in Biotech, host Ross Katz sits down with Paul Finn, Chief Scientific Officer at Oxford Drug Design, for a conversation on what it actually takes to find a drug molecule that works not just on paper but also in the lab, in the cell, and, ultimately, in the clinic. Paul brings four decades of experience across what became GSK, Pfizer, and a series of Oxford-area spinouts and has shepherded a compound all the way to a marketed drug. That perspective gives him a particular kind of skepticism toward AI results that look too good to be true because he's done the work of checking whether they are. The conversation moves through synthesizability as a first-class constraint, why chemistry has proven so much harder for AI than biology, how 3D molecular representation gets closer to the physics that actually matters, and what rigorous multi-parameter optimization looks like when you're trying to kill cancer cells and drug-resistant bacteria at the same time. What you'll learn in this episode: >> Why synthesizability is chronically underestimated and why changing a single atom in a structure can take a molecule from trivially easy to make to practically impossible >> How Oxford Drug Design constrains the generative search to reaction schemes and purchasable building blocks, and why that chemical space is still so vast that novelty is not meaningfully sacrificed >> Why most generative AI models learn from a 2D string representation of a molecule; two steps removed from the 3D physics that govern how a drug actually binds to its target >> How Bayesian optimization over reagent space, rather than molecular space, allows an active learning loop to focus on the structural patterns associated with activity >> Why benchmarking complex models against simple ones is the discipline that exposes false correlations and why Paul and his co-authors were able to recover the Halicin result using methods decades older than deep learning >> What a pharma company should actually ask an AI drug discovery vendor before buying what they're selling Meet our guest: Paul Finn is Chief Scientific Officer at Oxford Drug Design, a computational drug discovery company with roots in Oxford's chemistry department. His career spans over 40 years of computational drug discovery, from early structure-activity modeling in the 1980s through to modern generative AI methods, with deep experience at what became GSK and Pfizer before moving into the Oxford spinout ecosystem. At Oxford Drug Design, Paul leads internal programs in oncology and antibacterial resistance, combining novel computational methods with a rigorous, synthesizability-first approach to multi-parameter optimization. Connect with Paul Finn on LinkedIn: https://uk.linkedin.com/in/paul-finn-2250616 About the host: Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Ross Katz on LinkedIn: https://www.linkedin.com/in/b-ross-katz/ Connect with us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode! Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. https://www.linkedin.com/company/corrdyn/

ai discover design data 3d oxford principal rethinking pfizer 2d biotech chief scientific officer gsk molecule drug discovery data science lead

How GSK Built a Skills-Based Organisation in 18 Months

Play Episode Listen Later Jun 16, 2026 43:25

How do you rebuild a company's entire capability infrastructure — and fund the transformation through the savings it generates? Zaka Farhat is Global SVP for Talent, Learning, Organisation and Capability Development at GSK, where she leads the company's enterprise-wide skills, learning and capability agenda. In this episode, Zaka shares the full story of how GSK rebuilt its capability infrastructure in 18 months - retiring more than 20 legacy systems, building a single skills and learning ecosystem, and funding the transformation through the savings it generated. Join them as David and Zaka discuss:Why GSK's skills transformation began with a commercial question about capability and cost The five conditions for organisational readiness that had to be in place before any platform launched How GSK approached skills taxonomy, job architecture and inference, and what they had to redo along the way What personalised learning looks like at scale, and how skills data is now shaping workforce planning decisions What GSK chose to stop, and why decommissioning is the step most transformations skip How Zaka's team is measuring impact across three KPI layers This episode is sponsored by TechWolf. The world of work is being rewritten faster than HR systems can keep up. Skills age in months. Roles get redesigned quarter by quarter. CHROs have quietly become AI transformation leads, and the data they need to lead it doesn't exist in any HR system. That's why the world's most forward-looking enterprises such as HSBC, AMD, T-Mobile, GSK, ServiceNow, Pfizer, have built on TechWolf. As the data layer for the AI era of work, TechWolf gives enterprises the skills, they need to move faster and lead with confidence. Skills Intelligence, Work Intelligence, and Market Intelligence, in one layer. Visit techwolf.ai. Hosted on Acast. See acast.com/privacy for more information.

learning ai built talent skills acast roles pfizer organisation kpi t mobile amd hsbc servicenow gsk market intelligence zaka chros

Episode 186 - June 12, 2026

Biotech Clubhouse

Play Episode Listen Later Jun 12, 2026 61:29

On this week's episode, Graig Suvannavejh, Eric Schmidt, Paul Matteis and Financial Times' Oliver Barnes kicked off with the biotech market, with the XBI in positive territory and 12 biotech IPOs completed so far this year. They expected the IPO window to remain open for high-quality private companies. The group also overviewed recent financings, including SonoThera's $125 million Series B, City Therapeutics' $100 million Series B, Ethyreal's $101 million Series A, and Summit's decision to cancel a $500 million secondary offering. In data news, the co-hosts covered Tango's combination data with Revolution Medicines' RAS inhibitor. They also discussed Incyte's acquisition of Vega Therapeutics as a pipeline-building move ahead of Jakafi's 2028 patent expiration and J&J's acquisition of Firefly, with the RAS inhibitor space expected to remain hot. The group also discussed GSK's acquisition of Nuvalent -- its largest deal to date -- for two late-stage lung cancer assets. Oliver added perspective on biotech deal leaks, following the Incyte/Vega deal and GSK/Nuvalent deals this week. In partnership updates, Novartis expanded its molecular glue work with Orionis, Lilly licensed an Alzheimer's candidate from AlzeCure, and Corvus supported China partner Angel Pharmaceuticals. The episode concluded with the latest in rare disease and gene therapy, covering Novartis' FSHD program, FDA flexibility, Rett syndrome programs, and Sensorion's exit from hearing loss development. *This episode aired on June 12, 2026.

china summit alzheimer's disease fda ipo financial times tango firefly ras novartis series b gsk eric schmidt rett corvus incyte fshd xbi

Season 4 - Ep.11: Transcatheter treatment of tricuspid regurgitation - Carcinoid heart disease

Play Episode Listen Later Jun 11, 2026 21:47

This episode covers: Cardiology This Week: A concise summary of recent studies Transcatheter treatment of tricuspid regurgitation Carcinoid heart disease Milestones: MADIT-II Trial Host: Wilfried Mullens Guests: Stephan Baldus, Heidi Connolly and Konstantinos Koskinas Want to watch that episode? Go to: https://esc365.escardio.org/event/2560 Want to watch that extended interview on transcatheter treatment of tricuspid regurgitation, go to: https://esc365.escardio.org/event/2560?resource=interview Disclaimer ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own. Declarations of interests Stephan Achenbach, Yasmina Bououdina, Heidi Connolly, Nicolle Kraenkel and Wilfried Mullens have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. Stephan Baldus has declared to have potential conflicts of interest to report: research grant from Abbott, lecture fees from Abbott and Edwards. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

canada ai english treatments consulting edwards pfizer calgary esc statements abbott astrazeneca bayer philips heart disease merck johnson johnson gilead ferrer novartis declarations novo nordisk sanofi medtronic gsk amgen zoll abbvie bristol myers squibb takeda european society msd boehringer ingelheim deutsche gesellschaft inari regurgitation bial daiichi sankyo edwards lifesciences servier transcatheter bristol myers viatris alnylam sanofi aventis tricuspid carcinoid cardiology esc biotronik

Season 4 - Ep.11: Extended interview on transcatheter treatment of tricuspid regurgitation

OHNE AKTIEN WIRD SCHWER - Tägliche Börsen-News

Play Episode Listen Later Jun 11, 2026 11:34

Host: Wilfried Mullens Guest: Stephan Baldus Want to watch that extended interview, go to: https://esc365.escardio.org/event/2560?resource=interview Want to watch that entire episode? Go to: https://esc365.escardio.org/event/2560 Disclaimer ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own. Declarations of interests Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Wilfried Mullens have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. Stephan Baldus has declared to have potential conflicts of interest to report: research grant from Abbott, lecture fees from Abbott and Edwards. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

ChatGPT goes public: what the OpenAI IPO means for investors

AJ Bell Money & Markets

Play Episode Listen Later Jun 11, 2026 37:26

In this week's episode, Tom Sieber and Charlene Young digest the latest market developments from both sides of the Atlantic, with the company behind ChatGPT unveiling IPO plans, GSK unveiling its biggest deal in a decade and a UK market stalwart getting snapped up. Plus, as the World Cup gets underway, Tom discusses the winners off the pitch. Charlene talks us through changes to inheritance rules which could affect cohabiting couples and the things people should think about when passing on wealth to family and dependents. Tom reveals what readers of the latest free monthly Shares magazine can expect including the next phase of the AI story and how Netflix is looking to grow after missing out on acquiring Warner Bros. Finally, Charlene discusses plans to broaden access to mortgages in the UK and what they might mean for the property market and Tom and Charlene discuss some interesting new stats on pocket money. 00:00 Introduction 01:24 Markets: ChatGPT IPO, GSK's biggest deal in a decade & a UK takeover 16:19 Inheritance rules: cohabiting couples & passing on wealth 22:30 Shares magazine: AI's next phase & Netflix's growth plans 26:17 UK mortgage access & pocket money stats

netflix ai uk public chatgpt world cup atlantic investors warner bros inheritance ipo openai shares gsk

Telekom-Zerstörer Starlink und die verkannte Megatrend-Aktie

Alles auf Aktien

Play Episode Listen Later Jun 10, 2026 23:29 Transcription Available

In der heutigen Folge sprechen die Finanzjournalisten Lea Oetjen und Nando Sommerfeldt über wilde Kurse ohne Wert, das Draftkings-Comeback und die Lieblings-Lecker-Aktie. Außerdem geht es um SK Hynix, Samsung Electronics, Nvidia, Infineon, Siemens Energy, Aixtron, SUSS MicroTec, PVA TePla, Symrise, Nuvalent, GSK, J.M. Smucker, Deutsche Telekom, EchoStar, T-Mobile US, 1&1, Vodafone Group, Telefónica, Orange, BT Group, Telia Company, Freenet, Airbus, Rheinmetall, Hensoldt, OHB und MTU Aero Engines. Mit dem Code „AAAFRIENDS“ spart ihr 50 Prozent auf Eure Tickets beim Finance Summit am 2. Oktober – aber nur unter diesem Link: https://veranstaltung.businessinsider.de/event/financesummit26/summary?rp=c6dc55d6-6f4f-4fb4-b75f-3f3501d84859 Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Hier könnt ihr den AAA-Newsletter abonnieren: https://www.welt.de/newsletter/article232797673/Alles-auf-Aktien-Der-taegliche-Boersen-Newsletter-fuer-WELTplus-Abonnenten.html Und - ganz neu: AAA gibt es jetzt auch auf Instagram: https://www.instagram.com/alles_auf_aktien/ Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

mit welt alles hosts orange ihr gedanken noch ideen antworten nvidia wert aaa umsetzung starlink prozent kauf zerst airbus fonds kurse verlag telef aktien verluste megatrends gsk telekom finanz rabatte aktie deutsche telekom werbepartner rheinmetall impressum samsung electronics smucker infineon sk hynix echostar bt group t mobile us symrise ohb freenet vodafone group hensoldt zsch mtu aero engines aixtron

Allianz expandiert in Asien. Meta-Handwerker, SpaceX & ETFs, WM-Bier, Cadence

Play Episode Listen Later Jun 10, 2026 15:35

Zum SpaceX-Livestream von Christian Röhl und Scalable Capital: https://www.youtube.com/watch?v=yHUq95TUJhM Tech-Aktien unter Druck. OpenAI reicht IPO-Dokumente ein. GSK kauft Nuvalent. AB InBev profitiert von WM-Biernachfrage. Meta baut Handwerker-Akademie mit CBRE. Isar Aerospace holt 270 Mio. €. Iceye holt halbe Milliarde. Intel x Cadence. Applied x Hyper. Die Allianz (WKN: 840400) ist auf Einkaufstour in Asien und automatisiert mit Anthropic die Schadensprüfung. Rekordgewinn im Q1, KGV von 12 und fast 5% Dividendenrendite. SpaceX, OpenAI, Anthropic: Bis zu 350 Mrd. $ werden aus dem Markt gezogen. Kommt SpaceX in den S&P 500? Nein. In den NASDAQ 100? Ja. Christian Röhl erklärt, was das für uns alle bedeutet. Diesen Podcast vom 10.06.2026, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung. Learn more about your ad choices. Visit megaphone.fm/adchoices

spacex intel openai druck markt hyper nasdaq bier applied etfs anthropic asien allianz mio handwerker gsk cbre mrd ab inbev diesen podcast milliarde christian r scalable capital einkaufstour kgv dividendenrendite iceye isar aerospace rekordgewinn

Merck & Gilead's HIV Pill Breakthrough: Phase 3 Success! | Pharma and Biotech Daily

De Inside Beleggen Podcast van Trends

Play Episode Listen Later Jun 10, 2026 5:23

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The landscape of these industries is one of constant evolution, characterized by scientific advancements, strategic mergers, and regulatory maneuvers that shape the future of healthcare. In a significant scientific breakthrough, Merck & Co. and Gilead Sciences have made strides in HIV treatment with the development of a weekly pill. This innovative regimen combines Merck's islatravir with Gilead's lenacapavir, showing promise in two phase 3 trials. If approved, this long-acting oral therapy could revolutionize HIV care by offering a more convenient dosing schedule, potentially improving patient adherence and outcomes substantially. This novel regimen signifies progress towards simplifying HIV treatments with once-weekly dosing. Meanwhile, in the oncology sector, Gilead's Trodelvy faced challenges when combined with Merck's Keytruda as a first-line treatment for PD-L1-high non-small cell lung cancer. The phase 3 EVOKE-03 trial was terminated, shifting attention to competitors like AstraZeneca and Daiichi Sankyo, who continue to advance their own therapies in this area. In a strategic move to bolster its position in lung cancer treatment, GlaxoSmithKline (GSK) is acquiring Nuvalent for $10.6 billion, aiming to secure near-approval cancer therapies capable of challenging market leaders like Roche and Pfizer. This acquisition underscores the focus on targeted cancer therapies that increase treatment efficacy by honing in on specific genetic markers. Nuvalent's innovative pipeline of small molecule inhibitors targets drug resistance and mutations in cancer treatment—a strategic addition to GSK's portfolio aimed at enhancing its position amidst rapid advancements and intense competition in oncology. In diabetes and obesity management, Eli Lilly is advancing with its new oral GLP-1 receptor agonist, Foundayo (orforglipron), which has shown competitive efficacy over oral semaglutide. Analysts see Lilly's progress as strengthening its leadership in the growing obesity drug market. Similarly, AstraZeneca is making progress with its own GLP-1 candidate, elecoglipron, as phase 2 data sets the stage for pivotal studies. Promising clinical trial data from Eli Lilly's retatrutide for obesity-related conditions and AstraZeneca's elecoglipron suggest a strengthening pipeline for GLP-1 receptor agonists known for their dual effects on weight management and glycemic control. On the diagnostics front, Roche reaffirms its €600 million investment in Germany amid industry retrenchments by companies like Eli Lilly and Boehringer Ingelheim. However, Roche remains cautious about future risks due to shifting economic conditions. The financial dynamics within biotech are also noteworthy. Parabilis Medicines is planning a potentially record-setting IPO following Kailera Therapeutics' successful public offering earlier this year. These trends indicate strong investor confidence and an influx of funding towards innovative cancer therapies. Meanwhile, CeQur's $100 million Series E funding round aims at accelerating insulin patch delivery systems' commercial growth—highlighting ongoing innovation in diabetes management solutions. Regulatory updates reveal AstraZeneca facing reprimands from the UK marketing watchdog due to repeated breaches related to LinkedIn activities—an ongoing challenge in pharmaceutical marketing compliance. The integration of digital health solutions continues apace as ixlayer partners with Vertex Pharmaceuticals to launch a digital acute pain management platform. This initiative aims at improving patient care by reducing reliance on opioid-based treatments. These developments paint a picture of an industry where scientific innovations, regulatory hurdles, and technological advancements intersect to shape future therapeutic landscapes. Precision oncology is another area witnessing substantial growth. The landscape also sees notable activity in rare disease therapeutics. Johnson & Johnson's Talvey has gained acceptance in Scotland for treating relapsed multiple myeloma using bispecific antibody technology—a trend toward leveraging immune system targeting technologies to enhance cancer treatment efficacy. Moreover, Zai Lab's Tivdak received approval from China's NMPA for cervical cancer treatment based on Phase 3 data, highlighting the rise of antibody-drug conjugates (ADCs) as potent oncology therapies due to their targeted delivery mechanisms. On the research collaboration front, AlzeCure Pharma's partnership with Eli Lilly focuses on Alzheimer's disease research through Alzstatin ACD680—a small molecule targeting neurodegenerative pathways—a testament to the collaborative efforts needed to tackle complex diseases like Alzheimer's. However, challenges persist as Bial discontinued its GCase activator program after failing Phase 2b trials for Parkinson's patients with GBA1 variants—a stark reminder of the high-risk nature inherent in drug development despite initial promise. These myriad developments underscore a vibrant period within pharmaceutical and biotech sectors where scientific advancements rapidly translate into actionable therapies promising substantial improvements in patient care by addressing unmet medical needs globally.Support the show

Lilly tees off with Novo at ADA, GSK's $10.6B deal, FDA reform continues in Makary's absence

BioSpace

Play Episode Listen Later Jun 10, 2026 25:02

Everything came up roses for Eli Lilly at the American Diabetes Association, as the pharma boasted positive results for its new pill Foundayo and next-gen asset retatrutide—not just for weight loss but also for other indications.Obesity rival Novo Nordisk, meanwhile, held a dinner, during which executives may have convinced analysts that the company is turning a corner after a rough couple of years.Also check out ADA updates from Roche and partner Zealand Pharma, Boehringer Ingleheim, Pfizer (touting results from its Metsera buy), AstraZeneca, Kailera Therapeutics and more.Outside of ADA, the biggest news of the past week came on Tuesday with GSK striking the biggest traditional pharma/biotech M&A of the year so far with its $10.6 billion acquisition of oncology focused Nuvalent Bio. And on Monday, J&J notched a smaller deal, buying out Firefly Bio for $1B. These deals add to continued uptick in M&A seen in biopharma this year, with much of that momentum being driven by Eli Lilly and its GLP-1 cash.At an FDA listening meeting last week on the Commissioner's National Priority Voucher program, the agency heard multiple calls to pause it. Confusion also still persists around all of the new rare disease pathways, including the new plausible mechanism framework.

confusion fda reform commissioners pfizer obesity novo absence astrazeneca glp 1b roche eli lilly tees novo nordisk gsk american diabetes association zealand pharma

Z-Beurs woensdag 10/06/26 met Erik Joly

Play Episode Listen Later Jun 10, 2026 9:49

De Duitse industriële productie en export houden verrassend goed stand, merkt beursgast Erik Joly. De hoofdeconoom bespreekt ook de overname van Nuvalent door GSK en nieuws heet van de naald van champagnehuis Vranken Pommery. --- Trends Beleggen is een podcastkanaal van de redactie van Trends. Meer info en advies over beleggen vind je op https://trends.be/beleggen/ --- Elke dag beleggingsadvies in uw mailbox? Registreer u gratis op één van de e-newsletters op https://www.trends.be/newsletters --- Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

meer simplecast gsk woensdag beurs de duitse

9am Hour: Tech Extends Rebound, OpenAI Joins the IPO Race, Apple Unveils "Siri AI" at WWDC 6/9/26

Squawk on the Street

Play Episode Listen Later Jun 9, 2026 42:42

Carl Quintanilla and Jim Cramer led off the show with the tech sector bouncing back from Friday's sell-off for a second straight day. Hear what Jim said about the chip sector rebound. The anchors discussed OpenAI confidentially filing for an IPO after last week's Anthropic filing to go public — and SpaceX slated for its Wall Street debut on Friday. Also in focus: SpaceX's CFO on data centers in space, market reaction to Apple unveiling "Siri AI" at WWDC, GSK buys a cancer drug maker in a $10.6 billion deal, Nvidia CEO Jensen Huang makes his presence felt in South Korea — and dances. Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

apple race tech wall street south korea spacex cfo ipo siri openai rebound wwdc anthropic simplecast extends gsk jim cramer squawk carl quintanilla

Work Intelligence Playbook for CHROs in the AI Era

The Effective Statistician - in association with PSI

Play Episode Listen Later Jun 9, 2026 44:32

How do the world's most forward-thinking organisations use skills intelligence, market intelligence and work intelligence together to stay ahead? In this episode of the Digital HR Leaders podcast, host David Green is joined by Mik Wornoo, co-founder and President of US at TechWolf, to explore how organisations are using three signals together to build a strategic workforce planning strategy that can keep pace with AI, and what that looks like in practice. In this conversation, David and Mik discuss: What skills intelligence, work intelligence and market intelligence each bring to strategic workforce planning, and why all three matter What work intelligence actually means in practice, and how decomposing work into tasks is changing how organisations understand the impact of AI on their workforce How AI is actively reshaping roles right now, and what that means for strategic workforce planning, job architecture and redeployment Real-world case studies from organisations using all three signals to make smarter workforce decisions and align their people strategy with their AI strategy What it actually looks like to get started, and why the barrier to entry is lower than most HR leaders think This episode is sponsored by TechWolf. The world of work is being rewritten faster than HR systems can keep up. Skills age in months. Roles get redesigned quarter by quarter. CHROs have quietly become AI transformation leads, and the data they need to lead it doesn't exist in any HR system. That's why the world's most forward-looking enterprises such as HSBC, AMD, T-Mobile, GSK, ServiceNow, Pfizer, have built on TechWolf. As the data layer for the AI era of work, TechWolf gives enterprises the skills, they need to move faster and lead with confidence. Skills Intelligence, Work Intelligence, and Market Intelligence, in one layer. Visit techwolf.ai. Resources: TechWolf podcast Hosted on Acast. See acast.com/privacy for more information.

president ai real skills intelligence acast roles playbook pfizer t mobile amd hsbc mik servicenow gsk david green market intelligence chros

Tuesday's Morning Movers: MU Rebounds, ON PT Increases & GSK Buys NUVL

TD Ameritrade Network

Play Episode Listen Later Jun 9, 2026 6:35

Diane King Hall discusses this morning's top moving stocks by highlighting Micron (MU) as it rallies back after Friday's sell-off. She also touches on Wells Fargo raising its ON Semiconductor's (ON) price target to $140 from $115, and GSK's (GSK) new $10.6 billion acquisition of Nuvalent (NUVL).======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

ios buys increases wells fargo movers gsk sling rebounds vizio market minute

Understanding and Mitigating Endpoint Bias in External Control Arms

Play Episode Listen Later Jun 9, 2026 28:41 Transcription Available

External control arms are becoming increasingly important in drug development, but creating valid comparisons requires more than matching patient populations. In this episode, I speak with Ben Ackerman, Director of Real-World Biostatistics at GSK, about one of the most overlooked challenges in external control arm studies: endpoint bias. We discuss why differences in how outcomes are measured can influence study results, what researchers should consider when designing studies, and how the field is evolving to address these challenges. If you work with real-world evidence, causal inference, or innovative clinical trial designs, this episode offers valuable insights into improving the credibility and transparency of external control arm analyses.

director fda bias arms external epidemiology clinical trials mitigating gsk rwe drug development biostatistics endpoint real world evidence causal inference oncology research regulatory science comparative effectiveness research

Eli Lilly's Retatrutide Breakthrough: 30.3% Weight Loss Success | Pharma and Biotech Daily

astrazeneca repaso gsk la jornada kering rheinmetall viejo continente

Play Episode Listen Later Jun 9, 2026 4:35

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're delving into a series of groundbreaking advancements and strategic movements reshaping the landscape of drug development and patient care. Eli Lilly's retatrutide has emerged as a significant breakthrough in obesity treatment, demonstrating a remarkable 30.3% weight reduction over two years in a Phase 3 trial. This drug, a triple agonist targeting glucagon-like peptide-1 receptors, regulates appetite and energy balance effectively. Such results not only highlight its potential as a transformative therapy for obesity but also position Eli Lilly prominently within metabolic disorder treatment landscapes. With global obesity rates on the rise, retatrutide's success could meaningfully impact public health strategies and pharmaceutical approaches to managing weight. In the oncology sector, Johnson & Johnson's acquisition of Firefly Bio for $1 billion is a strategic move aimed at enhancing their oncology pipeline with Firefly's Degrader Antibody Conjugate platform. This technology is designed to target KRAS-driven tumors, which are notoriously difficult to treat, prevalent in cancers such as pancreatic and colorectal cancer. By integrating Firefly's innovative platform, J&J aims to offer new hope for patients dealing with these challenging cancers. Turning to regulatory developments, the FDA has expanded Pfizer's Hympavzi label to include pediatric patients aged six and older with hemophilia A and B. This decision follows robust Phase 3 results that demonstrate Hympavzi's efficacy as a prophylactic treatment in this young population. The expanded label underscores efforts to address pediatric needs in areas traditionally focused on adults, thus broadening treatment options for young patients with bleeding disorders. In Europe, Chiesi's Loxujta (lomitapide) has gained EU pediatric label expansion for treating homozygous familial hypercholesterolemia, supported by strong Phase 3 data. This expansion aligns with a growing trend toward personalized medicine, tailoring treatments to specific genetic profiles even in younger populations. Collaborative efforts in biotechnology are also gaining momentum. GSK has partnered with Engitix to research liver fibrosis regression through extracellular matrix-targeted drug discovery. This collaboration highlights an industry shift towards leveraging biotechnology for innovative therapeutic solutions. Hikma Pharmaceuticals has shown confidence in the U.S. pharmaceutical manufacturing sector by committing $267 million to expand its facilities in Ohio. This expansion enhances Hikma's production capabilities while creating 350 jobs, positively impacting local economies and ensuring robust supply chain capabilities for essential medicines. The clinical trial landscape is vibrant with promising data across various therapeutic areas. Amgen's Repatha (evolocumab) has demonstrated cardiovascular risk reduction in high-risk diabetes patients without prior heart attacks or strokes, reinforcing its role not just in cholesterol management but also in broader cardiovascular risk mitigation strategies. Dexcom has made strides in metabolic diseases with its G7 continuous glucose monitor showing significant benefits for non-insulin-dependent type 2 diabetes patients. This development illustrates the increasing integration of digital health technologies into chronic disease management. Moreover, emerging treatments like Sciwind Biosciences' ecnoglutide have shown superior weight loss outcomes compared to existing therapies such as semaglutide. Such head-to-head comparisons are crucial for advancing competitive therapeutic landscapes and optimizing patient outcomes. In summary, the pharmaceutical and biotech sectors are experiencing transformative changes driven by scientific advancements and strategic collaborations. These developments not only expand treatment options across various therapeutic areas but also signify a shift toward more personalized and integrated healthcare solutions that could significantly impact patient care and drug development pathways globally. As these trends continue to evolve, they will likely drive further progressions in how pharmaceutical companies approach drug development and regulatory engagements, ultimately benefiting patients worldwide through more effective and personalized treatment modalities. Stay tuned for more updates from Pharma Daily as we continue to bring you the latest insights from the world of pharmaceuticals and biotechnology.Support the show

europe ohio turning european union phase breakthrough fda pfizer collaborative g7 firefly pharma biotech eli lilly gsk amgen kras weight loss success dexcom chiesi hikma repatha

Repaso de la jornada en el Viejo Continente

Mercado Abierto

Play Episode Listen Later Jun 9, 2026 7:21

Rheinmetall, Kering, GSK, AstraZeneca... bajo la lupa de Alberto Roldán, profesor de finanzas de la Universodad Europea

La tech se remet la tête à l'endroit

La Chronique Finance

Play Episode Listen Later Jun 9, 2026 6:51

spotify finance wall street id flash orange spacex pas acc nasdaq visitez deezer investir abonnez gsk inscriptions bourse la tech investissement cryptomonnaies audiomeans remet

Cierre de Mercados 09/06/2026

Cierre de mercados

Play Episode Listen Later Jun 9, 2026 53:58

Adiós al proyecto de un caza de combate de sexta generación en el marco del programa FCAS, un proyecto de 100.000 millones de euros del que estaba previsto que viese la luz en la década de 2040. El programa ha estado paralizado hasta ahora por el enfrentamiento entre Airbus (que representa a Alemania) y Dassault (en representación de Francia) por ver quién se hacía cargo del desarrollo y fabricación de las partes más importantes del caza, un obstáculo que finalmente ha sido insalvable. Tras la caída definitiva de la colaboración con Francia, Airbus podría apuntar a hacer un nuevo avión de combate por su cuenta. El laboratorio británico GSK ha alcanzado un acuerdo para adquirir por 10.600 millones de dólares la biofarmacéutica estadounidense Nuvalent, centrada en el desarrollo de terapias oncológicas de alta precisión. Y el Consejo de Ministros ha aprobado este martes un Real Decreto-ley para impulsar la cuarta edición del programa “Verano Joven”. Hablaremos de movilidad sostenible y los temas de la actualidad, a debate en la Tertulia de Cierre de Mercados con Antonio Alvarez-Ossorio, del despacho de abogados Alvarez-Ossorio Miller.

tras francia hablaremos alemania cierre consejo airbus mercados ministros gsk tertulia dassault real decreto fcas

Legend Biotech's CAR T-Cell Breakthrough: 100% Response Rate | Pharma and Biotech Daily

Play Episode Listen Later Jun 4, 2026 5:50

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the most significant advancements in scientific research, clinical trials, and regulatory landscapes within the industry. These developments are shaping the future of patient care and drug development significantly. Starting with Legend Biotech's LB2501, which achieved an impressive 100% response rate in a Phase 1 study for non-Hodgkin lymphoma using in vivo CAR T-cell therapy. This breakthrough highlights the transformative potential of CAR T-cell therapies in oncology, especially for B-cell lymphomas. Such success opens the door for accelerated regulatory pathways, offering hope to patients with limited treatment options. In another key development, JJP Biologics shared positive interim data from its Phase 1b trial of nebaprubart targeting CD89 in linear IgA disease. This monoclonal antibody is promising in treating autoimmune conditions by targeting specific disease mechanisms. Meanwhile, GSK's Velzatinib (IDRX-42) achieved a 61% response rate in Phase 1/1b trials for gastrointestinal stromal tumors, showing efficacy against cases resistant to treatments like imatinib. Johnson & Johnson's Nipocalimab met its primary endpoint in a Phase 2 study for systemic lupus erythematosus, underscoring the potential of FcRn blockade in managing autoimmune diseases. Zenas Biopharma's Phase 3 data for Obexelimab targeting CD19/FcγRIIB in IgG4-related disease further emphasizes the role of targeted therapies in managing complex autoimmune disorders. On the regulatory front, Foundation Medicine's FoundationOne Blood Test received FDA approval as a companion diagnostic for Pfizer's Talzenna (talazoparib) to treat prostate cancer with homologous recombination repair gene mutations. This approval underscores the growing importance of precision medicine and companion diagnostics in tailoring cancer treatments based on genetic profiles. Additionally, Lupin and Natco Pharma secured FDA approval for their generic version of Eribulin Mesylate Injection, essential for reducing healthcare costs and improving patient access to vital therapies. Eli Lilly's collaboration with Ascidian Therapeutics focuses on RNA exon editing for kidney diseases, potentially revolutionizing treatment approaches by correcting genetic errors at the RNA level. This partnership reflects a burgeoning interest in RNA-based therapies and their capacity to address unmet medical needs. Regeneron expanded its pact with CytomX Therapeutics to develop conditionally active bispecific antibodies, emphasizing innovation in oncology drug discovery. Such collaborations combine expertise across companies to expedite cutting-edge therapies' development. In terms of funding, NewLimit's successful $435 million Series C round aims to advance epigenetic reprogramming medicine towards human trials. This initiative highlights the burgeoning field of aging biology and its implications for extending healthy human lifespan through innovative therapeutic approaches. Similarly, Immu Biosciences raised $53 million to enhance its immunology platform using AI/ML technologies, underscoring AI and machine learning's critical role in accelerating drug development processes. Turning our gaze towards China's expanding influence on the global biotech stage, Akeso's presentation at ASCO 2026 marked a significant milestone as it became the first-ever Chinese dataset featured in a plenary session. This achievement underscores China's growing prominence in biotechnology and highlights its commitment to advancing innovative medical solutions globally. Simultaneously, Gilead's strategic partnership with Cencora aims to enhance access to CAR-T therapies like Yescarta and Tecartus by expanding their network of treatment centers. CAR-T therapies represent a paradigm shift in cancer treatment by offering personalized options for certain types of cancer. Despite challenges such as Roche's setbacks with its oral SERD drug giredestrant in breast cancer trials, innovation continues unabated. Zevra Therapeutics' launch of Miplyffa for Niemann-Pick disease type C exemplifies efforts to transform rare disease markets by improving patient outcomes through increased access and tailored treatment strategies. Finally, Eli Lilly's acquisition spree reflects broader trends where pharmaceutical companies increasingly integrate Chinese innovations into their development pipelines. This period marks a transformative phase characterized by collaboration between global pharma giants and Chinese biotechs, signaling an era where innovation is globalized and aimed at addressing critical healthcare challenges worldwide. These advancements reflect a dynamic period of innovation within the pharmaceutical and biotech industries. The focus on personalized medicine, targeted therapies, and groundbreaking technologies like RNA editing indicates a shift towards more precise treatment modalities. As these discoveries transition from research phases to clinical applications, they hold the potential to transform patient care significantly. Strategic partnerships and substantial funding initiatives illustrate a robust ecosystem supporting these innovations' rapid advancement. As regulatory bodies continue approving novel therapeutics and diagnostics, the emphasis on personalized healthcare will likely drive future developments, ultimately leading to improved patient outcomes worldwide. As we continue navigating these developments, it's clear that the pharmaceutical and biotech sectors are on the cusp of transformative breakthroughs that promise to redefine healthcare delivery across multiple domains. Thank you for tuning into Pharma Daily; stay informed and stay ahead.Support the show

Moderna-Merck Combo Cuts Melanoma Risk by 49% | Pharma and Biotech Daily

Play Episode Listen Later Jun 3, 2026 5:15

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we dive into a series of groundbreaking advancements and strategic maneuvers reshaping the landscape of drug development and patient care. In recent news, Moderna and Merck & Co. have reported substantial progress in cancer treatment with their Phase 2b trial results involving Intismeran Autogene combined with Keytruda. This combination therapy, leveraging the innovative mRNA vaccine technology alongside Keytruda, has shown a remarkable 49% reduction in recurrence risk for high-risk melanoma patients. This synergy not only enhances therapeutic options in melanoma but also underscores the transformative potential of mRNA vaccines beyond infectious diseases, suggesting a new frontier for oncology treatments. Bristol Myers Squibb has also made significant strides with its Phase 3 trial results for Izalontamab Brengitecan, an antibody-drug conjugate. This therapy has demonstrated a 40% reduction in death risk among patients with triple-negative breast cancer—an aggressive subtype with historically limited treatment options. The success of this bispecific antibody targeting Trop2 highlights the advancing trend towards precision medicine, where therapies are increasingly tailored to specific genetic and molecular profiles, promising improved patient outcomes. Turning to business developments, Rallybio's merger with Avenzo Therapeutics through a reverse merger transaction marks a notable consolidation trend within the industry. Supported by a $215 million private placement, this merger aims to accelerate drug discovery and development in oncology, emphasizing the importance of strategic collaborations in enhancing therapeutic pipelines. Similarly, MindMaze Therapeutics is streamlining operations post-merger by refocusing on core competencies aligned with broader industry trends towards specialization. Regulatory updates have been equally dynamic. Shionogi's Xocova (Ensitrelvir) has received FDA approval for post-exposure prophylaxis against COVID-19 following successful Phase 3 trials. As a small-molecule protease inhibitor, Xocova enriches the therapeutic arsenal against COVID-19 and reflects ongoing efforts to manage infectious diseases even as the pandemic wanes. Strategic partnerships are further shaping the industry landscape. The collaboration between ASCO and Ryght AI aims to enhance breast cancer trial site selection using artificial intelligence. This initiative signifies a growing trend towards integrating AI and machine learning technologies in clinical trial optimization to streamline processes and improve efficiency—an essential endeavor as trials become more complex and data-driven. Additionally, Sanofi's integration of AI via field agents to enhance efficiencies across business facets highlights how AI adoption is accelerating and promises to reshape drug development processes and patient care strategies significantly. Meanwhile, challenges persist. The FDA's rejection of Cingulate's CTX-1301 due to manufacturing concerns underscores the rigorous regulatory environment that companies navigate. Similarly, Roche's Persevera trial missing its primary endpoint in breast cancer treatment highlights the inherent risks involved in drug development. In scientific advancements, Gilead Sciences has made progress with Livdelzi in treating primary biliary cholangitis (PBC), a rare liver disease. The Phase 3 trial success points to ongoing innovation in rare disease treatments—a critical area for enhancing patient outcomes. On another front, Contraline is advancing its male birth control candidate after securing $92.5 million in funding. This first-in-class topical contraceptive fills a significant gap in male contraceptive options, demonstrating an increasing focus on diversifying reproductive health solutions. In strategic shifts within the industry, Merck is reducing its workforce as part of a broader $3 billion cost-cutting strategy aimed at optimizing operations while investing in innovation and technology. At ASCO 2026, Celcuity shared ambitions to revolutionize breast cancer treatment paradigms through innovative pathway targeting, while GSK introduced a new approach for rare gut cancers—conditions that have seen little advancement over decades. Such initiatives highlight critical roles innovative research plays in oncology. In summary, these developments reflect a vibrant period for the pharmaceutical and biotech sectors characterized by scientific innovation, strategic mergers, regulatory milestones, and ongoing clinical trials that collectively promise to enhance patient care. Emphasis on personalized medicine, expansion of mRNA technology into oncology, and AI-driven efficiencies are poised to redefine approaches across therapeutic domains while navigating stringent regulatory standards and market dynamics that require strategic agility and robust R&D pipelines. Thank you for tuning into Pharma Daily—your source for insightful updates from the world of pharmaceuticals and biotechnology. Stay connected for more groundbreaking news and analysis shaping the future of healthcare.Support the show

Inside Lloyds Banking Group's People Transformation

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 2, 2026 51:10

What does it take to turn a 300-year-old bank into the UK's biggest fintech? Sharon Doherty is Chief People and Places Officer at Lloyds Banking Group, and over the last four years she's been leading one of the most ambitious organisational transformations in British financial services - 300-year-old institution reinventing itself as the UK's biggest fintech.In this episode, David and Sharon get into what transformation at that scale actually looks like from the inside - the governance, the culture work, the AI strategy, and the tough calls that only leadership can make. How Sharon thinks about her role as CPPO through three lenses: storyteller, tough lover, and disruptorThe AI governance structure at Lloyds, including the control tower she runs with the CTO and the ethics committee underpinning every decisionThe cross-functional super agent Lloyds is building with MicrosoftWhy HR leaders should be fighting to get Places on their remit, and how ownership of the physical environment transforms what the function can deliverHow Lloyds is approaching the shift from AI literacy to AI fluency across 80,000 peopleWhat Sharon thinks the world of work looks like in 2033, and the role HR must play in getting there This episode is sponsored by TechWolf. The world of work is being rewritten faster than HR systems can keep up. Skills age in months. Roles get redesigned quarter by quarter. CHROs have quietly become AI transformation leads, and the data they need to lead it doesn't exist in any HR system. That's why the world's most forward-looking enterprises such as HSBC, AMD, T-Mobile, GSK, ServiceNow, Pfizer, have built on TechWolf. As the data layer for the AI era of work, TechWolf gives enterprises the skills, they need to move faster and lead with confidence. Skills Intelligence, Work Intelligence, and Market Intelligence, in one layer. Visit techwolf.ai. Hosted on Acast. See acast.com/privacy for more information.

ai uk british transformation skills places acast roles cto pfizer t mobile amd hsbc servicenow gsk lloyds chief people market intelligence lloyds banking group chros

19%功能性治愈！治愈乙肝的曙光来了！

天方烨谈

Play Episode Listen Later May 30, 2026 2:49

GSK近日公布，其在研反义寡核苷酸药物bepirovirsen治疗慢性乙型肝炎的两项关键3期临床试验取得突破性阳性结果。数据同步发表于《新英格兰医学杂志》，并在欧洲肝脏研究学会年会上公布，有望改写全球慢乙肝治疗格局。

gsk

Charise Gleason, MSN, NP-C, AOCNP / Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO - “Off-the-Shelf” Choices in RRMM: Oncology Nurse Guidance on Delivering Quality Care With BCMA and Non-BCMA Immunotherapy

Play Episode Listen Later May 29, 2026 59:51

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/FJB865. NCPD/ILNA credit will be available until May 25, 2027.“Off-the-Shelf” Choices in RRMM: Oncology Nurse Guidance on Delivering Quality Care With BCMA and Non-BCMA Immunotherapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.

patients choices nurses guidance delivering disclosure oncology medical education gleason immunotherapy gsk faan off the shelf quality care accreditation council charise bcma pvi continuing medical education accme aocnp pharmacy education acpe practice aids peerview institute bmtcn

Bhavana Pothuri, MD, MS / Premal Thaker, MD, MS - Targeting With Precision in Advanced Ovarian Cancer: Integrating Approved and Novel Agents Into Personalized Treatment Plans

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later May 29, 2026 51:15

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/JUS865. CME/AAPA/IPCE credit will be available until May 28, 2027.Targeting With Precision in Advanced Ovarian Cancer: Integrating Approved and Novel Agents Into Personalized Treatment Plans In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK, Incyte Corporation, and Verastem Oncology.Disclosure information is available at the beginning of the video presentation.

patients treatments integrating targeting disclosure approved personalized precision medical education gsk ovarian cancer bhavana accreditation council pvi premal continuing medical education accme pharmacy education acpe national ovarian cancer coalition practice aids peerview institute

Bhavana Pothuri, MD, MS / Premal Thaker, MD, MS - Targeting With Precision in Advanced Ovarian Cancer: Integrating Approved and Novel Agents Into Personalized Treatment Plans

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later May 29, 2026 51:15

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/JUS865. CME/AAPA/IPCE credit will be available until May 28, 2027.Targeting With Precision in Advanced Ovarian Cancer: Integrating Approved and Novel Agents Into Personalized Treatment Plans In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK, Incyte Corporation, and Verastem Oncology.Disclosure information is available at the beginning of the video presentation.

Charise Gleason, MSN, NP-C, AOCNP / Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO - “Off-the-Shelf” Choices in RRMM: Oncology Nurse Guidance on Delivering Quality Care With BCMA and Non-BCMA Immunotherapy

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later May 29, 2026 59:51

Eli Lilly's Zepbound Coverage Restored! Breaking News | Pharma and Biotech Daily

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later May 29, 2026 5:43

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Recent updates offer a fascinating glimpse into an industry marked by dynamic shifts and groundbreaking advancements, each promising to reshape the future of healthcare. Let's delve into some of the most notable developments that are capturing attention across the globe. Starting with Eli Lilly's obesity medication, Zepbound, which has regained insurance coverage through CVS Caremark. This decision is emblematic of a broader recognition of obesity as a significant health issue that demands comprehensive treatment solutions. The reinstatement of coverage enables more patients to access Zepbound, potentially setting a benchmark for other insurers and leading to improved health outcomes. Shifting focus to oncology, AbbVie has secured FDA approval for a new therapy derived from its acquisition of ImmunoGen, adding to its portfolio of antibody-drug conjugates (ADCs) with Elahere. This development underscores the escalating value of ADCs in precision cancer therapies, offering innovative solutions for targeting cancer cells while preserving healthy tissues. Japan's pharmaceutical R&D stance is under examination as Prime Minister Sanae Takaichi meets with over 20 industry leaders to discuss maintaining the nation's competitive edge. This gathering highlights a global race among nations to enhance their R&D capabilities, ensuring leadership in pharmaceutical innovations. In neuroscience, Novartis's relentless pursuit to conquer the blood-brain barrier reflects ongoing efforts to revolutionize treatments for neurological disorders. Despite recent advancements, Novartis continues to explore new strategies for drug delivery to the brain, aiming to unlock therapies for conditions like Alzheimer's and Parkinson's disease. Viridian Therapeutics' collaboration with Wuxi Biologics marks a notable push in the eye drug market, positioning them against major players like Amgen. This partnership emphasizes manufacturing capability as a critical factor in ensuring resilient supply chains and competitive advantage. The hepatitis B treatment landscape has witnessed significant progress with GSK's phase 3 trial results for its drug Bepirovirsen. Achieving a functional cure in around one-fifth of patients signifies a major step forward in addressing this widespread disease. The potential to reduce lifelong antiviral therapy and lower liver cancer rates illustrates the transformative impact of nucleic acid-based therapies. Leadership dynamics also play a crucial role in pharma strategies. PharmaEssentia's appointment of Eric Vogel highlights the industry's reliance on seasoned talent to drive market expansion and broaden therapeutic indications, particularly for its rare blood cancer drug Besremi. In longevity research, Human Longevity's collaboration with Insilico Medicine introduces Human Life Foundation Models (HLFM), leveraging AI and genomics to extend human lifespan. This initiative is part of a broader trend integrating cutting-edge technologies into healthcare research, reflecting an evolving focus on longevity and genomic sciences. Regulatory landscapes are also evolving, as seen with CMS finalizing changes to the No Surprises Act dispute resolution process. By streamlining arbitration amidst rising disputes, these updates aim to refine healthcare policy frameworks for more efficient stakeholder service. Meanwhile, biosimilar approvals are gaining traction globally. ANVISA's approval of EMS's Ozivy in Brazil introduces a cost-effective alternative to Novo Nordisk's semaglutide (Ozempic) for type 2 diabetes. This step enhances access to affordable diabetes treatments, crucial for managing this prevalent metabolic disorder. In clinical trials innovation, D&D Pharmatech's Zabopegdutide has shown promising Phase 2 results for metabolic dysfunction-associated steatohepatitis (MASH), indicating fibrosis improvement and potential disease resolution. These findings underscore dual receptor agonists' therapeutic promise in tackling complex metabolic conditions. Additionally, Kailera Therapeutics' KAI-4729 demonstrates significant weight loss in Phase 1 obesity trials, potentially reshaping the obesity treatment landscape by offering superior weight management options compared to existing therapies. Funding rounds like Secretome Therapeutics' successful $30 million Series A highlight ongoing investments in regenerative medicine and cell-based therapies, propelling advancements in cardiovascular disease treatment pipelines. The acquisition landscape remains active with CordenPharma's purchase of AmbioPharm, expanding peptide manufacturing capabilities across U.S. and China markets. This move meets growing demand for peptide APIs vital in drug development processes. Technological innovation remains pivotal as Biohub releases an AI World Model for protein biology to expedite therapeutic discovery processes. This tool exemplifies computational biology's integration into drug discovery efforts, enhancing efficiency and innovation. Overall, these developments illustrate a vibrant pharmaceutical and biotech landscape characterized by scientific breakthroughs, strategic partnerships, regulatory achievements, and technological advancements—all aimed at advancing patient care and expanding therapeutic possibilities across diverse medical domains. As these trends continue unfolding, they promise not only improved treatment outcomes but also a more robust global healthcare ecosystem committed to innovation and excellence. Thank you for tuning into Pharma Daily; stay informed as we continue bringing you the latest from this rapidly evolving industry.Support the show

ai starting china leadership japan brazil shifting phase alzheimer's disease funding fda achieving breaking news parkinson coverage restored ozempic mash pharma regulatory apis ems biotech cms technological novartis eli lilly regenerative medicine novo nordisk gsk amgen semaglutide abbvie anvisa zepbound adcs no surprises act human longevity cvs caremark insilico medicine parkinson's disease eric vogel

Bhavana Pothuri, MD, MS / Premal Thaker, MD, MS - Targeting With Precision in Advanced Ovarian Cancer: Integrating Approved and Novel Agents Into Personalized Treatment Plans

Play Episode Listen Later May 29, 2026 51:15

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/JUS865. CME/AAPA/IPCE credit will be available until May 28, 2027.Targeting With Precision in Advanced Ovarian Cancer: Integrating Approved and Novel Agents Into Personalized Treatment Plans In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK, Incyte Corporation, and Verastem Oncology.Disclosure information is available at the beginning of the video presentation.

Charise Gleason, MSN, NP-C, AOCNP / Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO - “Off-the-Shelf” Choices in RRMM: Oncology Nurse Guidance on Delivering Quality Care With BCMA and Non-BCMA Immunotherapy

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later May 29, 2026 59:51

Bhavana Pothuri, MD, MS / Premal Thaker, MD, MS - Targeting With Precision in Advanced Ovarian Cancer: Integrating Approved and Novel Agents Into Personalized Treatment Plans

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later May 29, 2026 51:15

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/JUS865. CME/AAPA/IPCE credit will be available until May 28, 2027.Targeting With Precision in Advanced Ovarian Cancer: Integrating Approved and Novel Agents Into Personalized Treatment Plans In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK, Incyte Corporation, and Verastem Oncology.Disclosure information is available at the beginning of the video presentation.

Charise Gleason, MSN, NP-C, AOCNP / Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO - “Off-the-Shelf” Choices in RRMM: Oncology Nurse Guidance on Delivering Quality Care With BCMA and Non-BCMA Immunotherapy

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later May 29, 2026 59:51

Bhavana Pothuri, MD, MS / Premal Thaker, MD, MS - Targeting With Precision in Advanced Ovarian Cancer: Integrating Approved and Novel Agents Into Personalized Treatment Plans

PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast

Play Episode Listen Later May 29, 2026 51:15

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/JUS865. CME/AAPA/IPCE credit will be available until May 28, 2027.Targeting With Precision in Advanced Ovarian Cancer: Integrating Approved and Novel Agents Into Personalized Treatment Plans In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK, Incyte Corporation, and Verastem Oncology.Disclosure information is available at the beginning of the video presentation.

Episode 184 - May 29, 2026

Biotech Clubhouse

Play Episode Listen Later May 29, 2026 58:11

On this week's episode, Chris Garabedian, Brian Skorney, Graig Suvannavejh, and special guest Ginkgo Bioworks CEO, Jason Kelly, kick off with a market update, highlighting a continued positive sentiment, citing Endpoints' recent Biopharma Sentiment Index survey results, which showed improvements in biopharma conditions. The co-hosts also note the continued IPO activity, including Kardigan's recent filing. The conversation shifts to China, with Jason suggesting that genetic engineering is a strategic technology extending beyond therapeutics, warning that the U.S. is offshoring critical innovation to China. This sparks a debate with others noting that global collaboration is embedded in drug development and questioning whether restricting partnerships would ultimately harm U.S. competitiveness. In deals, the group highlights Lilly's acquisition of three vaccine companies for up to $3.8 billion and Apogee's $1.3 billion strategic collaboration with Blackstone to advance their eczema drug. The conversation shifts to data, with GSK's Phase 3 data for chronic hepatitis B drug, and an overview of datasets at ASCO 2026, including Revolution Medicines Phase 3 trial results for pancreatic cancer, which are expected to be the headline of the conference. The episode concludes with an overview of Biohaven's R&D Day, BMS in multiple myeloma, Dyne's DMD, and updates on the FDA following the recent leadership changes. after the departure of Dr. Marty Makary. *This episode aired on May 29, 2026.

china phase fda ipo d day blackstone gsk asco dmd bms marty makary apogee endpoints dyne jason kelly

Season 4 - Ep.10: Mitral annular disjunction - The heart in high altitude

Play Episode Listen Later May 28, 2026 17:22

This episode covers: Cardiology This Week: A concise summary of recent studies The heart in high altitude Mitral annular disjunction Mythbusters: Weekend mortality Host: Rick Grobbee Guests: JP Carpenter, Kristina Haugaa, Silvia Ulrich Want to watch that episode? Go to: https://esc365.escardio.org/event/2563 Want to watch that extended interview on mitral annular disjonction, go to: https://esc365.escardio.org/event/2563?resource=interview Disclaimer ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own. Declarations of interests Stephan Achenbach, Yasmina Bououdina, Rick Grobbee, Kristina Haugaa, Nicolle Kraenkel and Silvia Ulrich have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

canada ai english consulting pfizer calgary esc statements abbott astrazeneca bayer philips merck johnson johnson gilead ferrer novartis declarations novo nordisk sanofi medtronic gsk amgen zoll abbvie bristol myers squibb takeda european society msd high altitude boehringer ingelheim deutsche gesellschaft inari mitral bial daiichi sankyo annular edwards lifesciences servier bristol myers viatris alnylam sanofi aventis cardiology esc biotronik disjunction

Season 4 - Ep10: Extended interview on mitral annular disjunction

Play Episode Listen Later May 28, 2026 10:43

Host: Rick Grobbee Guest: Kristina Haugaa Want to watch that extended interview on https://esc365.escardio.org/event/2563?resource=interview Go to: Want to watch that episode? Go to: https://esc365.escardio.org/event/2563 Disclaimer ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own. Declarations of interests Stephan Achenbach, Yasmina Bououdina, Rick Grobbee, Kristina Haugaa and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

canada ai english consulting pfizer calgary esc statements abbott astrazeneca bayer philips merck johnson johnson gilead ferrer novartis declarations novo nordisk sanofi medtronic gsk amgen zoll abbvie bristol myers squibb takeda european society msd boehringer ingelheim deutsche gesellschaft inari mitral bial daiichi sankyo annular edwards lifesciences servier bristol myers viatris alnylam sanofi aventis cardiology esc biotronik disjunction

Why Meetings Are a System Design Problem

Real Talk: Eosinophilic Diseases

Play Episode Listen Later May 26, 2026 55:31

Are your meetings actually working? Or has your calendar just become a system nobody knows how to switch off? In this episode, David Green is joined by Rebecca Hinds, Stanford-trained organisational researcher, Head of the Work AI Institute at Glean, and author of Your Best Meeting Ever: 7 Principles for Designing Meetings That Get Things Done. In this conversation, David and Rebecca discuss: Why organisations should treat meetings as a product, and what that actually means in practice The concept of meeting debt, and why calendars accumulate bloat in the same way codebases accumulate technical debt What a 48-hour calendar cleanse involves, and what typically happens when organisations rebuild their calendars from scratch The patterns that show up most consistently when mapping how work actually moves between teams How AI is being used to improve meetings, and the ways it can make dysfunctional meeting culture worse What the conversation looks like in the room when CHROs start rethinking collaboration for the AI era This episode is sponsored by TechWolf. The world of work is being rewritten faster than HR systems can keep up. Skills age in months. Roles get redesigned quarter by quarter. CHROs have quietly become AI transformation leads, and the data they need to lead it doesn't exist in any HR system. That's why the world's most forward-looking enterprises such as HSBC, AMD, T-Mobile, GSK, ServiceNow, Pfizer, have built on TechWolf. As the data layer for the AI era of work, TechWolf gives enterprises the skills, they need to move faster and lead with confidence. Skills Intelligence, Work Intelligence, and Market Intelligence, in one layer. Visit techwolf.ai. Resources: Your Best Meeting Ever: 7 Principles for Designing Meetings That Get Things Done Hosted on Acast. See acast.com/privacy for more information.

head ai skills principles stanford acast roles meetings pfizer t mobile amd hsbc servicenow gsk glean david green market intelligence system design chros

An overview of Rome V

Gut Talk

Play Episode Listen Later May 22, 2026 44:40

In this episode, Lin Chang, MD, and Jan Tack, MD, PhD, discuss the history and evolution of Rome criteria, developing guidelines for multifactorial disorders in Rome V and more. · Lin Chang, MD, and Jan Tack, MD, PhD 1:04 · How has the Rome Foundation evolved over the last ten years? 4:26 · What are the Rome criteria, and why should clinicians care about them? 7:20 · How did these guidelines become the Rome criteria? 10:32 · What is the timeline of developing these criteria? 12:35 · Can you tell us about how the Rome Foundation got to the name "DGBI", and why it makes sense for multifactorial conditions? 22:22 · What are the highlights and most important changes from Rome V? 26:38 · How will this information be disseminated so clinicians can learn about it? 34:22 · What lessons did you learn from the Rome V process? 37:40 · What's next for the Rome Foundation? 40:04 Lin Chang, MD, is professor of medicine and vice chief of the Vatche and Tamar Manoukian Division of Digestive Diseases at David Geffen School of Medicine at UCLA. Jan Tack, MD, PhD, is president of the Rome Foundation. He also serves as professor of medicine at KU Leuven and chief of the division of gastroenterology and hepatology at Leuven University Hospitals. We'd love to hear from you! Send your comments/questions to guttalkpodcast@healio.com. Follow us on X @HealioGastro @sameerkberry @umfoodoc. Disclosures: Chey and Tack report no financial disclosures. Chang reports consulting roles with Ardelyx, Atmo, Eli Lilly & Co., FoodMarble, GSK, Ironwood Pharmaceuticals and Ono Pharmaceutical; speaking fees from Bausch Health; research grants from AnX Robotica and Ironwood; serving on the Rome Foundation Board of Directors; and having unvested stock options with FoodMarble, ModifyHealth, PICO Health and Trellus Health. Reference: · Drossman DA, et al. Gastroenterology. 2026;doi:10.1053.j.gastro.2026.02.014.

director phd medicine rome md ucla chang tack gsk gastroenterology ku leuven david geffen school ironwood atmo digestive diseases foodmarble ironwood pharmaceuticals

Community Conversation: EoE

Play Episode Listen Later May 21, 2026 31:22

Co-hosts Ryan Piansky, a graduate student and patient advocate living with eosinophilic esophagitis (EoE) and eosinophilic asthma, and Holly Knotowicz, a speech-language pathologist living with EoE who serves on APFED's Health Science Advisory Council, interview Phillip Arceneaux, PhD, on his journey with EoE and balancing his career. Disclaimer: The information provided in this podcast is designed to support, not replace, the relationship between listeners and their healthcare providers. Opinions, information, and recommendations shared in this podcast are not a substitute for medical advice. Decisions related to medical care should be made with your healthcare provider. Opinions and views of guests and co-hosts are their own. Key Takeaways: [:50] Co-host Ryan Piansky introduces this episode, brought to you thanks to the support of Education Partners GSK, Sanofi, Regeneron, and Takeda. Ryan introduces co-host Holly Knotowicz. [1:12] Holly introduces today's topic. It's May, and each year in May, there are several awareness observances for eosinophilic-associated diseases, including National Eosinophil Awareness Week, World Eosinophilic Diseases Day, and World EoE Day. [1:29] Throughout May, APFED is sharing stories from individuals and families living with eosinophil-associated diseases to highlight the impact of these chronic conditions. [1:38] Ryan says, Today, we'll be discussing eosinophilic esophagitis (EoE). EoE is a chronic allergic inflammatory disease of the esophagus. It occurs when eosinophils, a type of white blood cell, accumulate in the esophagus in elevated numbers, causing inflammation that can make eating or swallowing difficult or uncomfortable. [1:56] Holly introduces today's guest, Dr. Phillip Arceneaux, a patient advocate living with EoE since 2019. [2:18] Phil is 35. He was born and raised in Lafayette, Louisiana. He received his undergraduate degree there. He worked at the U.S. Naval Academy in Annapolis, Maryland. Then he worked at the University of Oregon. [2:38] Phil moved to Florida and did his Ph.D. in Mass Communication at the University of Florida. Since 2020, he has been based out of the Cincinnati area, working at Miami University of Ohio. [3:05] Phil was diagnosed with EoE in March of 2019, while finishing his degree at UF. [3:12] Phil was eating dinner with his girlfriend. He took a bite of a roast beef sandwich, and it didn't go down smoothly, it became impacted. [3:56] Phil thought he had food stuck in his windpipe. He was running around banging his chest. He calmed down and was able to get some of the food out, and he was breathing again. [4:12] Phil thought he was fine. He quickly realized he wasn't. He still had a partial impaction. He didn't know what was going on in his chest. He spent about 30 minutes moving around, coughing, and trying to get his chest to feel right. [4:44] After about an hour, Phil decided to go to the ER. His girlfriend insisted on driving him to the hospital. It was spring break, so the ER was not busy. It still took a couple of hours to be seen and treated. [5:25] The doctors assessed him. They gave him medicine to induce vomiting. About 12 hours after the initial choking, his impaction cleared. They kept him overnight and gave him an endoscopy in the morning to check his esophagus and take biopsies. [6:31] Phil was in the ER for four to six hours before anyone told him what they thought he had. Then the ER doctor told him he was 95% certain Phil had eosinophilic esophagitis. Phil had never heard of it. [7:04] The ER doctor gave Phil a rundown of EoE. He said Phil would have an endoscopy, and then he would be referred to a GI and set up for treatment. The doctor said he couldn't confirm it before the endoscopy, but he thought it was EoE. [7:31] Ryan says he's talked to people who have had months-long processes of getting their diagnosis. Phil gives all the credit to the hospital. He was fortunate that his experience was good. [7:55] Phil says that the staff at the ER and the GI specialist were so knowledgeable about the research and where things were going in this area of medicine. They were very confident about the diagnosis and treatment plan. [8:11] Dr. Arcenaux gives a shout-out to his GI. He spent well over an hour with him during his initial consult. He explained how EoE would impact him, from diet, grocery shopping, and challenges eating at restaurants, because of cross-contamination. [8:42] The GI specialist talked him through impacts on dating and dining out and how to approach social activities. [9:09] Phil's GI specialist talked to him about employers. He would need employers with health insurance that will cover the endoscopies and treatments for EoE. Phil appreciated the initial onboarding for his EoE diagnosis. [9:41] Ryan says he needs to discuss this with Phil, as he just finished his Ph.D. a few months ago, and he's looking at insurance for his new job, and how to figure out business lunches. [9:51] Ryan says Ph.D. students are so motivated by free food. As someone with EoE, that never applied to him. Ryan says shifting from normal eating habits to an EoE diet is a major shift. [10:27] Phil knows now that there were signs and symptoms, but he had no idea about them before his diagnosis. [10:33] Phil is on a special diet for his EoE. When he's not great at avoiding his trigger foods, he starts to see dysphagia symptoms in his swallowing, and he has quite a bit of regurgitation. He had been seeing that for months before this initial major food impaction and ER visit. [10:54] Phil had no idea what was going on. He just thought it was weird that he was regurgitating more than he used to. Sometimes food didn't go down well. Once or twice, he had a small aspiration event. He thought he needed to chew better. [11:11] He didn't know what those symptoms meant, and he wrote them off. None of it made sense until that diagnosis. Even then, it took a while to wrap his head around it. Years removed, he sees there were so many signs and symptoms he never processed. [11:28] Holly asks what Phil means by aspiration. He says he means water going down his windpipe, making it hard to breathe, with liquid in his lungs. Holly says that aspiration can be caused by inflammation in people who have EoE. [12:07] Holly says people with EoE can be sent for a swallow study to look at the anatomy of their swallow function. That's a subject for another episode! [12:35] Ryan says Phil noticed he was regurgitating more than normal and remarks that people with chronic illnesses don't realize that most people don't normally regurgitate at all. It's a sign that something's wrong. [13:03] The ER doctor didn't offer Phil any other diagnosis than EoE. The doctor was 95% sure he had EoE, but confirmed it with an endoscopy. [13:20] Holly asks Phil what food allergies he has. As an infant, he had an egg allergy that limited his vaccines. Now he knows his primary allergen is egg, and it led to his EoE issues. [13:51] When Phil started his Ph.D. program, he wanted to eat healthier foods. He cut out fast food, and he ate more eggs. He consumed many eggs during his Ph.D. program. A snack was scrambled eggs or something with scrambled eggs. [14:22] Phil went through a carton of 18 eggs in less than a week. He knew that when he was younger, he'd had egg sensitivity, but as an adult, he'd eaten eggs and nothing happened that registered as an issue. He thought he had outgrown it. [14:40] Phil says he had outgrown other food allergies. He assumed eggs were fine, so he adopted a heavy egg diet to increase his protein intake and be healthier. Then all these symptoms manifested. [15:00] Phil never associated the symptoms with eggs. His treatment plan is dieting and minimizing egg as much as possible. That is not easy in the United States, where everything is processed and often contains egg. [15:19] Holly says she has seen an influx of adult-onset EoE patients with a history of a dairy or egg allergy who were putting cottage cheese and eggs in everything, and all of a sudden, started having regurgitation and food getting stuck. [15:51] Phil doesn't eat scrambled eggs anymore. One slice of a cake with eggs in it will not send him to the ER. It takes a couple of days of high exposure to reach that point. He knows what he can have daily that will not impact him in the long term. [16:20] Holly and Ryan agree that it's important to know your limits, and consult with your physicians about foods. Rice is a trigger for Ryan, but if brown rice syrup is about the 20th ingredient, he can have it and be fine. If he were to eat a lot of rice, he will have issues. [17:21] Phil says he recently got married, and his wife is a health nut. She has radically changed his diet. They eat very high-protein, low-fat, and low-carb. It's been easy to manage that without eggs. They eat a lot of chicken, turkey, and fish. [17:41] Being from Louisiana, Phil says if he had to give up seafood, he doesn't know what he would do. He's a huge craft beer lover. If he had to give up gluten, he doesn't know what he would do. He can manage without eggs. [18:21] Ryan says dairy was a big trigger for him when he was younger, but now he's on dupilumab, a biologic approved for treating EoE, and that's helped him a lot. He's started to integrate whey protein and milk protein back into his diet. [18:47] Phil says once he finished with school, he graduated and lost health insurance. He didn't have a source of income or health insurance, so he declined to have dilation therapy. That's also why he deferred to dietary therapy. He removed his allergens one by one. [19:12] Phil was diagnosed in 2019, not long before the pandemic hit. He lived in a bubble for two to three years and kept to a very regimented diet. That's where he started to find his balance. [19:30] Phil travels quite a bit as a professor. He goes to international conferences. In 2022, a big annual conference opened in Paris, France. He was living his best life, but didn't register that every pastry he put in his mouth had an egg wash. [20:14] Phil was there for seven days. On the sixth night, he was eating a tough, dry steak. He had a severe food impaction, worse than the one in 2019. He was with colleagues who didn't know what he had. [20:40] He paid, excused himself, went to his hotel room, and tried to vomit it up. He couldn't do it. He called an Uber and went to the nearest ER. He had an emergency endoscopy. It's not easy to navigate another country's healthcare system, but he did it. [21:14] When Phil returned from the conference, he said he needed to get serious. He had a GP, but he needed a GI specialist. Cincinnati has multiple great health systems, so he got a GI specialist and started down a path of treatment. [21:38] He told his GI specialist, this has happened to me, and I never want it to happen again. What can we do? He started with proton pump inhibitors. No effect. He doesn't have acid reflux. Next was the topical corticosteroid, swallowed budesonide. [22:22] Phil used a pump for asthma, but this was to swallow. After two weeks, he developed a bad case of thrush that took a long time to get rid of. He had never had thrush and didn't know what it was. It took a couple of rounds of treatment to clear up. [22:43] After that, in 2022, he moved to dupilumab. The FDA had just approved it as a course of treatment for EoE. Phil did not do well with the treatment, and has since gone back to back to a diet-only course of treatment. [24:13] Phil says the dupilumab shots did help. He had been having reactions to some foods for years, and after a couple of weeks on the shot, those reactions went away, and he could eat the foods, like avocado and watermelon, again. [24:39] The dupilumab did him some good, as he returned to some foods that he loved, but it wasn't a long-term solution for him. [24:50] Ryan shares that he started his Ph.D. in 2019. He felt great, he had no symptoms, and he was following up with his GI every year. With no symptoms, he wasn't scoped until 2025 for insurance reasons. His scope was horrible. [25:11] His symptoms were in remission, but his esophagus looked terrible. He had to switch up his treatment plan. Ryan advises all listeners to follow up with their GI. [26:14] Phil says he thinks he's in a very lucky position that what his allergen is, what his dietary preferences are, and how he manifests symptoms, do not significantly impact his day-to-day. [26:36] Phil's doctor in 2019 had advised him that EoE would impact his work and his business lunches. With the treatment plan he has opted into, it doesn't impact his day-to-day. He says he is very lucky, compared to what other patients deal with. [26:50] It hasn't impacted his day-to-day, but the problem is, when it does impact something. It's very big, very noticeable, and it's in front of everyone. He recalls his Paris episode. He's very vocal about it. That's why he reached out to APFED. [27:13] Phil likes talking about it. The only way we know more about it is when we talk about it and share our stories. His colleagues all know he has EoE. They don't understand exactly what it is, but when he's having trouble, they understand. [27:44] When Phil has an issue, he doesn't tell anyone; he just gets up and walks out of the room and paces the hall, doing his stretches. [28:09] Largely, it's just letting people know he has EoE. They recognize that he manages it himself, and he's OK. [28:24] Phil says figuring out your medical treatment plan and balancing your quality of life is different from having a disease that can eventually be treated. [28:51] This is something you have to deal with the rest of your life. That's going to fundamentally change things, not drastically, but in fairly subtle ways. [29:18] No matter how comfortable you get, you have to be diligent. You always have to be cognizant of your symptoms and stay on whatever your treatment plan is, whether that's dieting or medication. This will not go away. You're always going to have it. [29:37] Phil says you have to frame it as a lifelong marathon and find a very sustainable pace. That's where the quality of life is so important. We're human beings. We have to enjoy life. Settle in for the long haul. That's how it will be sustainable. [30:18] Ryan thinks self-advocacy is important, whether talking with doctors, co-workers, or friends. Take care of yourself and make sure you're doing OK. Make sure you're putting yourself in a position to stay healthy, especially while balancing a career. [30:45] Ryan says those are great things for our listeners to keep in mind. [30:49] For our listeners who do want to learn more about eosinophilic disorders, we encourage you to visit APFED.org and check out the links in the show notes below. [30:55] If you're looking to find a specialist who treats eosinophilic disorders, we encourage you to use APFED's Specialist Finder. available at APFED.org/specialist. [31:04] If you have personally been impacted by eosinophilic disorders and are interested in sharing your experience, please check out APFED.org/shareyourstory. [31:12] If you'd like to connect with others impacted by eosinophilic diseases, please join APFED's online community on the Inspire Network at APFED.org/connections. [31:23] Ryan thanks Phil for joining us today. This was a super interesting conversation. Phil thanks Ryan and Holly for having him on. He is happy to represent on the podcast. [31:35] Holly thanks APFED's Education Partners GSK, Sanofi, Regeneron, and Takeda for supporting this episode. Mentioned in This Episode: APFED on YouTube, Twitter, Facebook, Pinterest, Instagram Real Talk: Eosinophilic Diseases Podcast Apfed.org apfed.org/specialist apfed.org/connections Phillip Arceneaux, PhD Education Partners: This episode of APFED's podcast is brought to you thanks to the support of GSK, Sanofi, Regeneron, and Takeda. Tweetables (Edited): "I took a bite of a roast beef sandwich, and it wasn't going down smoothly. I drank some water. The bite became an impaction. The water stayed in my esophagus, and I started to aspirate." — Phillip Arceneaux, Ph.D. "The ER doctor told me he was 95% certain I had eosinophilic esophagitis. I had never heard of it. He gave me a quick rundown of what it was." — Phillip Arceneaux, Ph.D. "I want to give a shout-out to my GI. He spent well over an hour in my initial consult. He explained how [EoE] would impact me, from diet, grocery shopping, and eating at restaurants, because of cross-contamination." — Phillip Arceneaux, Ph.D. "I never associated the symptoms with eggs. My treatment plan is diet and minimizing egg as much as possible. That is not easy in the United States." — Phillip Arceneaux, Ph.D. "This is something you have to deal with the rest of your life. That's going to fundamentally change things, not drastically, but in fairly subtle ways." — Phillip Arceneaux, Ph.D. "No matter how comfortable you get, you have to be diligent. You always have to be cognizant of your symptoms and stay on whatever your treatment plan is, whether that's dieting or medication. This will not go away. You're always going to have it." — Phillip Arceneaux, Ph.D. Guest Bio: Dr. Phillip Arceneaux is an Assistant Professor of Strategic Communication at Miami University in Ohio, where he teaches mass communication courses focusing on media psychology and content strategy. Phil was diagnosed with EoE in 2019 following an ER visit to UF Health Shands Hospital that required an emergency endoscopy. A Cajun French native of Lafayette, Louisiana, he earned his Ph.D. from the University of Florida and has resided in Cincinnati since 2020.

The Case for a Four-Day Week: What the Research Shows

ai research skills acast roles future of work pfizer t mobile amd hsbc servicenow gsk david green market intelligence chros how hr four day week

Play Episode Listen Later May 19, 2026 54:47

Most organisations are asking how to get more from their people. But what if the real question is how to get more from the time they spend at work? In this episode of the Digital HR Leaders podcast, David Green is joined by Joe O'Connor, founder of Worktime Revolution, and Jared Lindzon, future-of-work journalist and author, to explore the research-backed case for the four-day working week, and what it means for how HR leaders design, lead and transform work. Join them as they discuss: Why the five-day working week is a relic of the industrial age What the evidence from global pilots shows about productivity, wellbeing and retention Why organisations moving to a four-day week are also becoming faster AI adopters What it actually takes to make the transition work - and why culture and trust are the real foundations How HR leaders can shift the conversation from top-down mandate to shared, enthusiastic change This episode is sponsored by TechWolf. The world of work is being rewritten faster than HR systems can keep up. Skills age in months. Roles get redesigned quarter by quarter. CHROs have quietly become AI transformation leads, and the data they need to lead it doesn't exist in any HR system. That's why the world's most forward-looking enterprises such as HSBC, AMD, T-Mobile, GSK, ServiceNow, Pfizer, have built on TechWolf.As the data layer for the AI era of work, TechWolf gives enterprises the skills, they need to move faster and lead with confidence. Skills Intelligence, Work Intelligence, and Market Intelligence, in one layer. Visit techwolf.ai. Resources: Do More In Four by Joe O'Connor and Jared Lindzon Hosted on Acast. See acast.com/privacy for more information.

#112 Ian Rudolph - Regenerative Design

Edifice Complex Podcast

Play Episode Listen Later May 15, 2026 97:06

Quality, Consequences and the Construction Industrial Complex (part 467)Our guest this episode is Ian Rudolph talking about regenerative design, training and qualifying as an Architect, insurance and much more.If you enjoy this episode, share it with friends and give us a review, it helps more than you know.In this episode, we discuss:De-construction materials as waste in the wrong spaceDe-construction rather than demolition60% of UK waste generated by constructionActual regenerative projectsAnd much more…….More on IanIan on LinkedIn: https://www.linkedin.com/in/ian-rudolph-9396a512/Marks Barfield Architects: https://marksbarfield.com/Marks Barfield Architects Circular Economy Explainer: https://marksbarfield.com/projects/beyondsustainability/22 Baker Street case study: https://marksbarfield.com/projects/22-baker-street/Oasis Nature Building Case Study: https://marksbarfield.com/oasis-nature-building/The Lantern Case Study: https://marksbarfield.com/projects/the-lantern-75-hampstead-road/BioIan Rudolph BA (Hons) Arch, Dip (Hons) Arch ARB RIBA, is a Director at Marks Barfield Architects in London UK. A qualified architect since 1995, Ian began his career in Germany designing energy efficient mass-timber buildings. Today, he oversees a talented team delivering bespoke, low-carbon projects across the UK and internationally.Marks Barfield Architects, winner of over 100 awards, works across education, arts, culture, workplace, residential, and infrastructure sectors, advancing sustainable and circular design principles. Previously, Ian led major projects at Sheppard Robson, including Santander's London HQ and research facilities for Imperial College London, GSK, and MRC. His focus now is on integrating regenerative design into every facet of architectural practice

director uk germany consequences architects rudolph santander imperial college london gsk london uk baker street mrc regenerative design london hq

Season 4 - Ep.9: Heart Failure 2026 Special - Biomarkers in heart failure - Digoxin in HFrEF - Heart Failure 2026 Scientific Highlights